Rationale: Regorafenib represents a treatment option in heavily pretreated patients affected by metastatic colorectal cancer (mCRC). Its safety profile is typical of small-molecule tyrosine-kinase inhibitors (TKIs) and most adverse events are manageable.
Introduction
The introduction of regorafenib has increased overall survival (OS) in patients with metastatic colorectal cancer (mCRC) who had previously received all standard therapies, as shown in the CORRECT study. [1] Although advantage in median OS between the experimental arm and the control arm was only 1.4 months, the hazard ratio (HR) of 0.77 produced a 23% reduction in risk of death during the course of the study in this population of patients with a poor prognosis and a high clinical unmet needs.
Regorafenib also showed to be effective in terms of progressionfree survival (PFS) and disease control rate and, at present, it may be considered a new standard of care in late-stage mCRC.
The safety profile of regorafenib is typical of small-molecule tyrosine-kinase inhibitors (TKIs). In the CORRECT trial the most frequent adverse events (AEs) of grade 3 or higher were hand-foot skin reaction, fatigue, diarrhea, hypertension, rash, and desquamation. Occurrence of liver toxicity was higher in the regorafenib than in the placebo group; the difference was attributable mainly to grade 1 or 2 events, but 1 fatal case of drug-induced liver injury was reported. Hyperammonemic encephalopathy (HE) related to regorafenib use has reported only in 1 patient with advanced GIST, [2] and it is a rare occurrence even with other TKIs. To our knowledge, this is the 1st case of HE under regorafenib treatment in a patient affected by mCRC with normal hepatic reserve.
Case report
A 56 years-old Caucasian man, affected by hypertension under treatment control, was referred to our Center in July 2014 and underwent left emicolectomy with lymph nodes dissection for a pT4a pN2b moderately differentiated mucinous adenocarcinoma of descending colon; mutational analysis of RAS and BRAF shown a wild-type sequence. Computed tomography (CT) scan at diagnosis did not demonstrate any secondary lesion. From September 2014 to May 2015 12 courses of adjuvant chemotherapy with FOLFOX-4 regimen were administered. In June 2015, the CT scan showed 4 metastases in the right lobe of the liver (2.5 cm maximum diameter) and 2 pulmonary metastases in the lung (1.3 cm maximum diameter). In July 2015, a 1st-line chemotherapy with FOLFIRI plus bevacizumab was started; after 8 courses of chemotherapy, the CT scan showed a progressive disease according to RECIST criteria, [3] with 3 new liver metastases in the right lobe (1.6 cm maximum diameter). On 7th January 2016, 4 weeks after the last FOLFIRI-Bevacizumab administration, regorafenib was started at standard dose of 160 x0200A;mg daily, for the 1st 3 weeks of each 4 week cycle. After only 2 days of therapy, the patient presented to the emergency department of a zone hospital due to impairment of both spatial and temporal orientation and motor function with bradylalia. On admission liver function tests and complete blood count were normal, but serum ammonia level was 191 mmol/L (thrice the upper normal range of 60 mmol/L). The patient was not an alcohol addicted nor treated with cytochrome P450 inducers or inhibitors. A brain CT scan excluded any intracranial pathology; an abdominal ultrasound (US) confirmed the presence of liver metastases, in absence of biliary ducts distension or signs of portal hypertension. No cardiac or pulmonary alterations were found. Regorafenib was withheld and branched chain amino acids and lactulose was administered, with a complete resolution of the confusional status in 24 hours. After 3 days the patient was discharged, and in 10 days serum ammonia level returned within the normal range (57 mmol/L). Regorafenib was thereafter restarted at a lower dose level (80 mg daily every 3 weeks of a July 2014 : leŌ emicolectomy with lymph nodes dissecƟon for a pT4a pN2b moderately differenƟated mucinous adenocarcinoma of descending colon. Liver function tests and complete blood count were normal, while serum ammonia level was 195 mmol/L so branched chain amino acids and lactulose were restored with rapid improvement of the cognitive status. Regorafenib was definitely interrupted and a rescue treatment was started. This AE was reported to the local drug control committee. The sequence of events is reported in Fig. 1 .
Discussion
Regorafenib is an oral inhibitor of angiogenic, oncogenic, and stromal kinases and of the RAF/MEK/ERK signaling pathway. The expected AEs of regorafenib are similar to those reported with other multitarget TKIs (hypertension, hand-foot syndrome, diarrhea, etc.); other rare AEs include hepatotoxicity, hemorrhage, gastrointestinal perforation, myocardial infarction, and reversible posterior leukoencefalopathy syndrome (RPLS). [4] RPLS is a neurological syndrome characterized by headache, seizures, impaired vision, acute hypertension, and typical imaging findings (bilateral edema of the gray and white matter in the posterior regions of cerebral hemispheres); its pathogenesis depends on capillary endothelium damage in the brain due to hypertension leading to capillary leak and brain edema. [5] HE has been reported in patients receiving chemotherapy, mostly in patients with hematologic malignancies during neutropenic phases following cytoreductive therapy and high-dose chemotherapy for bone marrow transplantation, or in patients with solid tumors treated with fluorouracil, as well as in patients affected by either primary hepatocellular carcinoma or neuroendocrine tumor with liver metastases. [6] [7] [8] Hyperammonemia occurs when ammonia is either overproduced or insufficiently eliminated from the serum; HE is an uncommon alteration in mental status that may arise in the absence of obvious liver disease. [9] Several cases of RPLS have been reported for either regorafenib or other TKIs, [10] [11] [12] but -at the best of our knowledge -only 5 cases of HE associated to TKIs have been described in literature. [2, [13] [14] [15] Among these, only 1 case of regorafenibinduced HE is described, [2] whereas the other have been related to sorafenib (1 case) and sunitinib (3 cases). [13, 15] In 4 out of 5 patients, liver was involved as primary or metastatic site of disease; in all cases HE was developed after about 2 week after the start of TKI therapy and resolution of symptoms occurred mostly after 24 to 72 hours after stopping treatment and starting of antihyperammonemic therapy (Table 1) . In our patient, the presence of hyperammonia and normal liver function supports the hypothesis of drug-induced metabolic encephalopathy.
Actually, he had a limited metastatic load with normal liver and renal tests, and no typical clinical and radiological features of RPLS were present, thus supporting the exclusion of a neurologic drug induced disease. No interactions with liver enzymes were known as the patient did not take any concomitant drugs and is not a drinker. In addition, the very close time relationship between drug administration and the onset of neurological symptoms and their recurrence on regorafenib rechallenge strongly support a causative role of regorafenib. The Naranjo scale suggests a probable adverse drug reaction with a score of 7, [16] even if a plausible biological explanation for the potential neurotoxicity of regorafenib would remain to be established. An interference of TKIs in cerebral signaling pathways regulated by tyrosine kinases or a distress due to their antiangiogenic action leading to brain suffering in patients with predisposing conditions have been hypnotized as possible mechanisms. [14] Hyperammonemia without any sign of liver impairment has also been reported in a Japanese study in which sunitinib was administered to a patient affected by GIST; the authors suggested that this AE might be caused, in part, by a vascular disorder related to the antiangiogenic properties of sunitinib. [17] Anyhow, genetic polymorphisms in pharmacokinetic and pharmacodynamic pathways can also be suggested as a possible cause of this phenomenon.
Our case is the 2nd of HE associated with regorafenib and the 1st case in a patient affected by mCRC. Discontinuation of regorafenib after confirmation of hyperammonemia is strongly recommended; reintroduction of the therapy at lower doses after resolution of symptoms related to HE has to be discouraged.
